HBV core particles as a carrier for B cell/T cell epitopes

Intervirology

Volumn 44, Issue 2-3, 2001, Pages 98-114

  Pumpens, Paul ^a   Grens, Elmars ^a  

^a UNIVERSITY OF LATVIA   (Latvia)

Author keywords

Antigenicity; Chimeric proteins; Epitopes; Hepatitis B virus core particles; Immunogenicity; Molecular display; Self assembly; Virus like particles

Indexed keywords

AMINO ACID; BACTERIAL PROTEIN; CARRIER PROTEIN; CORE PROTEIN; EPITOPE; PROTOZOAL PROTEIN; VIRUS PROTEIN; VIRUS VACCINE;

AMINO ACID SEQUENCE; ARTICLE; B LYMPHOCYTE; CYTOMEGALOVIRUS; DIAGNOSTIC PROCEDURE; FOOT AND MOUTH DISEASE VIRUS; GENE THERAPY; HANTAVIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS E VIRUS; HUMAN RHINOVIRUS; INFLUENZA VIRUS; LEUKEMIA VIRUS; NONHUMAN; PAPILLOMA VIRUS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; VIRUS ASSEMBLY; VIRUS CORE; VIRUS EXPRESSION; VIRUS PARTICLE; VIRUS RECOMBINANT;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, VIRAL; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; GENE THERAPY; HEPATITIS B VIRUS; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; VACCINES, SYNTHETIC; VIRAL CORE PROTEINS; VIRAL VACCINES;

BACTERIA (MICROORGANISMS); BOVINAE; CYTOMEGALOVIRUS; ENTEROBACTERIA PHAGE T4; FELIDAE; FELINE LEUKEMIA VIRUS; FOOT-AND-MOUTH DISEASE VIRUS; HANTAVIRUS; HEPATITIS B VIRUS; HUMAN RHINOVIRUS SP.; INFLUENZA VIRUS; MOUSE CYTOMEGALOVIRUS 1; MURINAE; POLIOVIRUS; PROTOZOA; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0034889864     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000050037     Document Type: Article

References (180)

1. New approaches to FMDV antigen presentation using vaccinia virus
2. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein
3. Recombinant capsid structures for exposure of protein antigenic epitopes
4. Functions of hepatitis B virus proteins and molecular targets for protective immunity
5. Hepatitis B virus nucleocapsid assembly
6. Hepatitis B
7. The hepatitis nucleocapsid as a vaccine carrier moiety
8. Hepatitis B virus core particles as epitope carriers
9. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety. I. Presentation of foreign epitopes
10. Core particles of hepatitis B virus as carrier for foreign epitopes
11. Hepatitis B core particles as a universal display model: A structure-function basis for development
12. The core antigen of hepatitis B virus as a carrier for immunogenic peptides
13. Expression of cloned hepatitis B virus DNA in human cell cultures
14. Expression of the hepatitis B virus surface, core and E antigen genes by stable rat and mouse cell lines
15. Core and E antigen synthesis in rodent cells transformed with hepatitis B virus DNA is associated with greater than genome length viral messenger RNAs
16. Expression of hepatitis B antigens with a simian virus 40 vector
17. Expression of hepatitis B viral core region in mammalian cells
18. Expression of the hepatitis B virus core gene in vitro and in vivo
19. Expression of hepatitis B virus surface and core antigens: Influences of pre-S and precore sequences
20. The secretory core protein of human hepatitis B virus is expressed on the cell surface
21. Vaccinia virus recombinants co-expressing hepatitis B virus surface and core antigens
22. Expression mechanism of the hepatitis B virus (HBV)C gene and biosynthesis of HBe antigen
23. A signal peptide encoded within the precore region of hepatitis B virus directs the secretion of a heterogeneous population of e antigens in Xenopus oocytes
24. Coexpression of the hepatitis B surface and core antigens using baculovirus multiple expression vectors
25. Expression of hepatitis B virus core and precore antigens in insect cells and characterization of a core-associated kinase activity
26. Physico-chemical analysis of the hepatitis B virus core antigen produced by a baculovirus expression vector
27. Generation of replication-competent hepatitis B virus nucleocapsids in insect cells
28. Expression of hepatitis B virus core antigen gene in Saccharomyces cerevisiae: Synthesis of two polypeptides translated from different initiation codons
29. Unusually high-level expression of a foreign gene (hepatitis B virus core antigen)in Saccharomyces cerevisiae
30. Purification and characterization of the hepatitis B virus core antigen produced in the yeast Saccharomyces cerevisiae
31. Production of hepatitis B virion-like particles in yeast
32. Application of the human hepatitis B virus core antigen from transgenic tobacco plants for serological diagnosis
33. Expression in Escherichia coli of hepatitis B virus DNA sequences cloned in plasmid pBR322
34. Hepatitis B virus genes and their expression in E. coli
35. Synthesis of hepatitis B surface and core antigens in E. coli
36. Hepatitis B virus core antigen: Synthesis in Escherichia coli and application in diagnosis
37. Structure and expression in Escherichia coli cells of the core antigen gene of the human hepatitis B virus
38. Precore sequence of hepatitis B virus inducing e antigen and membrane association of the viral core protein
39. Expression and characterization of hepatitis B virus precore-core antigen in E. coli
40. Total chemical synthesis of a gene for hepatitis B virus core protein and its functional characterization
41. The effect of the structure of the terminal regions of the hepatitis B virus gene C polypeptide on the formation of core antigen (HBcAg) particles
42. Comparison of three different recombinant hepatitis B virus core particles expressed in Escherichia coli
43. Production in B. subtilis of hepatitis B core antigen and of major antigen of foot and mouth disease virus
44. Hepatitis B virus nucleocapsid/pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination
45. Expression of the core antigen gene of hepatitis B virus (HBV) in Acetobacter methanolicus using broad host-range vectors
46. Electron microscopy of hepatitis B core antigen synthesized in E. coli
47. Electron microscopy of hepatitis B virus core antigen expressing yeast cells by freeze-substitution fixation
48. Evolutionary conservation in the hepatitis B virus core structure: Comparison of human and duck cores
49. Posttranscriptional regulation of hepatitis B virus replication by the precore protein
50. Replication of hepatitis B virus
51. Selection of peptide inhibitors of interactions involved in complex protein assemblies: Association of the core and surface antigens of hepatitis B virus
52. Both pre-S1 and S domains of hepatitis B virus envelope proteins interact with the core particle
53. Peptides that block hepatitis B virus assembly: Analysis by cryomicroscopy, mutagenesis and transfection
54. Effect of core protein phosphorylation by protein kinase C on encapsidation of RNA within core particles of hepatitis B virus
55. Phosphorylation and nuclear localization of the hepatitis B virus core protein: Significance of serine in the three repeated SPRRR motifs
56. Roles of the three major phosphorylation sites of hepatitis B virus core protein in viral replication
57. In vitro model for the nuclear transport of the hepadnavirus genome
58. Phosphorylation-dependent binding of hepatitis B virus core particles to the nuclear pore complex
59. Three dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy
60. Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy
61. Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy
62. The crystal structure of the human hepatitis B virus capsid
63. Genetically engineered mutants of the core antigen of the human hepatitis B virus preserving the ability for native self-assembly
64. A recombinant hepatitis B core antigen polypeptide with the protamine-like domain deleted self-assembles into capsid particles but fails to bind nucleic acids
65. Synthesis of hepatitis B virus e antigen in E. coli
66. The arginine-rich carboxy-terminal domain is necessary for RNA packaging by hepatitis core protein
67. Hepatitis B virus nucleocapsid assembly: Primary structure requirements in the core protein
68. C-terminal polyarginine tract of hepatitis B core antigen is located on the outer capsid surface
69. Assembly and antigenicity of hepatitis B virus core particles
70. Dimorphism of hepatitis B virus capsids is strongly influenced by the C-terminus of the capsid protein
71. Yeast Ty retrotransposons assemble into virus-like particles whose T-numbers depend on the C-terminal length of the capsid protein
72. Antibody to hepatitis-B-virus core in man
73. Hepatitis B virus immunopathogenesis
74. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen
75. Preferential recognition of hepatitis B nucleocapsid antigens by Th1 or Th2 cells is epitope and major histocompatibility complex dependent
76. The hepatitis B virus core and e antigens elicit different Th cell subsets: Antigen structure can affect Th cell phenotype
77. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site
78. Role of B cells in antigen presentation of the hepatitis B core
79. Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: Evidence that T cells are directed against HBV core antigen expressed on hepatocytes
80. The hepatitis B virus persists for decades after patients recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response
81. Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus
82. Characterisation of a linear binding site for a monoclonal antibody to hepatitis B core antigen
83. Human and murine B-cells recognize the HBeAg/β (or HBe2) epitope as a linear determinant
84. Immunochemical structure of the carboxy-terminal part of hepatitis B e antigen: Identification of internal and surface-exposed sequences
85. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen
86. Gamma-interferon production in response to hepatitis B core protein and its synthetic peptides in patients with chronic hepatitis B virus infection
87. Anergic TH1 clones specific for hepatitis B virus (HBV) core peptides are inhibitory to ther HBV core-specific CD4+ T cells in vitro
88. Immune response to hepatitis B virus core antigen (HBcAg): Localization of T cell recognition sites within HBcAg/HBeAg
89. Functional identification of agretopic and epitopic residues within an HBcAg T cell determinant
90. Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein
91. HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis
92. Purification and characterization of a naturally processed hepatitis B virus peptide recognized by CD8+ cytotoxic T lymphocytes
93. DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice
94. DNA vaccination with plasmids encoding the intracellular (HBcAg) or secreted (HBeAg) form of the core protein of hepatitis B virus primes T cell responses to two overlapping Kb- and Kd-restricted epitopes
95. Characterization of CD8+ cytotoxic T-lymphocyte responses after genetic immunization with retrovirus vectors expressing different forms of the hepatitis B virus core and e antigens
96. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles
97. Expression in yeast of amino-terminal peptide fusions to hepatitis B core antigen and their immunological properties
98. Presentation and immunogenicity of viral epitopes on the surface of hybrid hepatitis B virus core particles produced in bacteria
99. Foreign epitopes in immunodominant regions of hepatitis B core particles are highly immunogenic and conformationally restricted
100. Stimulation of specific immune responses to simian immunodeficiency virus using chimeric hepatitis B core antigen particles
101. Identification and characterization of a protective immunodominant B cell epitope f pertactin (P. 69) from Bordetella pertussis
102. Introduction of heterologous epitopes at the N-terminal part of the hepatitis B core protein
103. Characterization of potential insertion sites in the core antigen of hepatitis B virus by the use of a short-sized model epitope
104. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity
105. Expression of HIV gag and env B-cell epitopes on the surface of HBV core particles and analysis of the immune responses generated to those epitopes
106. Expression of HIV-1 epitopes included in particles formed by human hepatitis B virus nucleocapsid protein
107. HIV-1 epitopes exposed by hybrid hepatitis B core particles affect proliferation of peripheral blood mononuclear cells from HIV-1 positive donors
108. Expression of a human cytomegalovirus gp58 antigenic domain fused to the hepatitis B virus nucleocapsid protein
109. Puumala (PUU) hantavirus strain differences and insertion positions in the hepatitis B virus core antigen influence B-cell immunogenicity and protective potential of core-derived particles
110. HBV core particles allow the insertion and surface exposure of the entire potentially protective region of Puumala hantavirus nucleocapsid protein
111. A universal influenza A vaccine based on the extracellular domain of the M2 protein
112. Finding the small difference: A nine amino acid extension to the hepatitis B core protein. Electron microscopy
113. Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model
114. New chimaeric hepatitis B virus core particles carrying hantavirus (serotype Puumala) epitopes: Immunogenicity and protection against virus challenge
115. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids
116. Recombinant HBV core particles carrying immunodominant B-cell epitopes of the HBV preS2-region
117. Hybrid hepatitis-B virus core/pre-S particles expressed in live attenuated Salmonellae for oral immunization
118. A virulent Salmonella expressing hybrid hepatitis B virus core/pre-S genes for oral vaccination
119. Spatial structure and insertion capacity of immunodominant region of hepatitis B core antigen
120. Display vectors. I. Hepatitis B core particle as a display moiety
121. Expression and immunological analysis of hepatitis-B core fusion particles carrying internal heterologous sequences
122. The principal neutralizing determinant (V3) of HIV-1 induces HIV-1-neutralizing antibodies upon expression on HBcAg particles
123. Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles
124. Hybrid hepatitis B virus nucleocapsid bearing an immunodominant region from hepatitis B virus surface antigen
125. Heterologous epitopes in the central part of the hepatitis B virus core protein
126. Design of immunogens as components of a new generation of molecular vaccines
127. Chimeric hepatitis B core antigen particles containing B- and Th-epitopes of human papillomavirus type 16 E7 protein induce specific antibody and T-helper responses in immunised mice
128. Immunisation of mice using Salmonella typhimurium expressing human papillomavirus type 16 E7 epitopes inserted into hepatitis B virus core antigen
129. Differences in the effectiveness of delivery of B- and CTL-epitopes incorporated into the hepatitis B core antigen (HBcAg) c/e1-region
130. Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes
131. Theileria annulata sporozoite antigen fused to hepatitis B core antigen used in a vaccination trial
132. Evaluation of recombinant sporozoite antigen SPAG-1 as a vaccine candidate against Theileria annulata by the use of different delivery systems
133. Baculovirus expression of chimeric hepatitis B virus core particles with hepatitis E virus epitopes and their use in a hepatitis E immunoassay
134. Chimeric hepatitis B virus core particles as probes for studying peptide-integrin interactions
135. Modified hepatitis B core particles as possible vaccine carriers
136. Behavior of a short preS1 epitope on the surface of hepatitis B core particles
137. Expression, assembly competence and antigenic properties of hepatitis B virus core gene deletion variants from infected liver cells
138. Analysis of foreign epitope inserts in HBcAg. Approaches to solving the problem f core particle self-assembly
139. Insertion of foreign epitopes in HBcAg: How to make the chimeric particle assemble
140. Recombinant core particles of hepatitis B virus exposing foreign antigenic determinants on their surface
141. Hepatitis B virus core antigen as a carrier for functionally active epitopes: Exposure of preS regions on the capsids (in Russian)
142. Immunodominance of T-cell epitopes on foreign sequences of the hepatitis B virus nucleocapsid fusion proteins
143. Characterization of chimeric core particles of HBV containing foreign epitopes
144. Exposure of HIV-1 gp41 transmembrane protein epitopes on the surface of hepatitis B core antigen capsids (in Russian)
145. Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope
146. Immunogenicity of peptide fusions to hepatitis B virus core antigen
147. Mutated epitopes of hepatitis B surface antigen fused to the core antigen of the virus induce antibodies that react with the native surface antigen
148. Relationship between antigenicity and immunogenicity of chimeric hepatitis B virus core particles carrying HIV type 1 epitopes
149. Immunogenicity f recombinant core particles of hepatitis B virus containing epitopes of human immunodeficiency virus 1 core antigen
150. Exposure of major immunodominant epitope of bovine leukemia virus envelope protein gp51 on the surface of hepatitis B core antigen capsids (in Russian)
151. Sites in the core antigen of HBV allowing insertion of foreign epitopes
152. A new strategy to generate mosaic HBcAg particles presenting foreign epitopes
153. Bacterial synthesis of immunogenic epitopes of foot-and-mouth disease virus fused either to human necrosis factor or to hepatitis B core antigen (in Russian)
154. Chimeric hepatitis B virus core particles with parts or copies of the hepatitis C virus core protein
155. Association of hepatitis C virus carrier state with the occurrence of hepatitis C virus core antibodies
156. Hepatitis C virus core protein fused to hepatitis B virus core antigen for serological diagnosis of both hepatitis C and hepatitis B infections by ELISA
157. Localization and reactivity of an immunodominant domain in the NS3 region of hepatitis C virus
158. Construction and immunologic evaluation of a Porphyromonas gingivalis subsequence peptide fused to hepatitis B virus core antigen
159. Packaging of up to 240 subunits of a 17kDa nuclease into the interior of recombinant hepatitis B virus capsids
160. Determination of the minimal length of preS1 epitope recognized by a monoclonal antibody which inhibits attachment of hepatitis B virus to hepatocytes
161. Large surface proteins of hepatitis B virus containing the pre-S sequence
162. Mosaic hepatitis B virus core particles allow insertion of extended foreign protein segments
163. 2+-chelate affinity chromatography
164. Protection against hepatitis B virus infection by immunization with hepatitis B core antigen
165. Hepatitis B virus antigens made in microbial cells immunise against viral infection
166. Protective immunisation against hepatitis B with an internal antigen of the virus
167. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen
168. Polyvalent vaccination against hepatitis B surface and core antigen using a dicistronic expression plasmid
169. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection
170. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus
171. Immunization with recombinant woodchuck hepatitis virus nucleocapsid antigen or hepatitis B virus nucleocapsid antigen protects woodchucks from woodchuck hepatitis virus infection
172. Characterization of T-cell response to woodchuck hepatitis virus core protein and protection of woodchucks from infection by immunization with peptides containing a T-cell epitope
173. Development of recombinant Salmonellae expressing hybrid hepatitis B virus core particles as candidate oral vaccines
174. Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination
175. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety. II. Expression in avirulent Salmonella spp. for mucosal immunization
176. Immunization with hybrid hepatitis B virus core particles carrying circumsporozoite antigen epitopes protects mice against Plasmodium yoelii challenge
177. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-ecoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system
178. Chimeric hepatitis B core antigen particles as a presentation system of foreign protein epitopes (in Russian)
179. Isolation and study of recombinant strains of Salmonella typhimurium SL 7207, producing HBcAg and HBcAg-HBs (in Russian)
180. A new genotype of hepatitis B virus: Complete genome and phylogenetic relatedness